ABSTRACT
The Hippo pathway, a signaling cascade that controls cell cycle progression, apoptosis and cell differentiation, has emerged as a fundamental regulator of many physiological and pathological processes. Recent studies have revealed a complex network of interactions directing Hippo pathway activity, and have connected this pathway with other key signaling pathways. Such crosstalk has uncovered novel roles for Hippo signaling, including regulation of TGFß/SMAD and WNT/ß-catenin pathways. This review highlights some of the recent findings in the Hippo field with an emphasis on how the Hippo pathway is integrated with other pathways to mediate diverse processes.
Subject(s)
Drosophila Proteins/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Acyltransferases , Cell Cycle Proteins , Humans , Nuclear Proteins/metabolism , Signal Transduction/physiology , Transcription Factors/metabolism , Transforming Growth Factor beta/metabolism , Wnt Proteins/metabolismABSTRACT
Advanced glycation end products (AGEs) may play a role in the pathogenesis of diabetic nephropathy, by modulating extracellular matrix turnover. AGEs are known to activate specific membrane receptors, including the receptor for AGE (RAGE). In the present study, we analyzed the various receptors for AGEs expressed by human mesangial cells and we studied the effects of glycated albumin and of carboxymethyl lysine on matrix protein and remodelling enzyme synthesis. Membrane RAGE expression was confirmed by FACS analysis. Microarray methods, RT-PCR, and Northern blot analysis were used to detect and confirm specific gene induction. Zymographic analysis and ELISA were used to measure the induction of tPA and PAI-1. We show herein that cultured human mesangial cells express AGE receptor type 1, type 2 and type 3 and RAGE. AGEs (200 microg/ml) induced at least a 2-fold increase in mRNA for 10 genes involved in ECM remodelling, including tPA, PAI-1 and TIMP-3. The increase in tPA synthesis was confirmed by fibrin zymography. The stimulation of PAI-1 synthesis was confirmed by ELISA. AGEs increased PAI-1 mRNA through a signalling pathway involving reactive oxygen species, the MAP kinases ERK-1/ERK-2 and the nuclear transcription factor NF-kappaB, but not AP-1. Carboxymethyl lysine (CML, 5 microM), which is a RAGE ligand, also stimulated PAI-1 synthesis by mesangial cells. In addition, a blocking anti-RAGE antibody partially inhibited the AGE-stimulated gene expression and decreased the PAI-1 accumulation induced by AGEs and by CML. Inhibition of AGE receptors or neutralization of the protease inhibitors TIMP-3 and PAI-1 could represent an important new therapeutic strategy for diabetic nephropathy.
Subject(s)
Extracellular Matrix Proteins/genetics , Glycation End Products, Advanced/pharmacology , Matrix Metalloproteinase 2/genetics , Mesangial Cells/drug effects , Antibodies/pharmacology , Blotting, Northern , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Extracellular Matrix Proteins/metabolism , Flavonoids/pharmacology , Flow Cytometry , Gene Expression/drug effects , Humans , Lysine/analogs & derivatives , Lysine/pharmacology , Matrix Metalloproteinase 2/metabolism , Mesangial Cells/cytology , Mesangial Cells/metabolism , Norleucine/pharmacology , Oligonucleotide Array Sequence Analysis , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/metabolism , Receptor for Advanced Glycation End Products , Receptors, Immunologic/genetics , Receptors, Immunologic/immunology , Receptors, Immunologic/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-3/genetics , Tissue Inhibitor of Metalloproteinase-3/metabolism , Tissue Plasminogen Activator/genetics , Tissue Plasminogen Activator/metabolism , alpha-Macroglobulins/genetics , alpha-Macroglobulins/metabolismABSTRACT
As a component of the apoptosome, a caspase-activating complex, Apaf-1 plays a central role in the mitochondrial caspase activation pathway of apoptosis. We report here the identification of a novel Apaf-1 interacting protein, hepatocellular carcinoma antigen 66 (HCA66) that is able to modulate selectively Apaf-1-dependent apoptosis through its direct association with the CED4 domain of Apaf-1. Expression of HCA66 was able to potentiate Apaf-1, but not receptor-mediated apoptosis, by increasing downstream caspase activity following cytochrome c release from the mitochondria. Conversely, cells depleted of HCA66 were severely impaired for apoptosome-dependent apoptosis. Interestingly, expression of the Apaf-1-interacting domain of HCA66 had the opposite effect of the full-length protein, interfering with the Apaf-1 apoptotic pathway. Using a cell-free system, we showed that reduction of HCA66 expression was associated with a diminished amount of caspase-9 in the apoptosome, resulting in a lower ability of the apoptosome to activate caspase-3. HCA66 maps to chromosome 17q11.2 and is among the genes heterozygously deleted in neurofibromatosis type 1 (NF1) microdeletion syndrome patients. These patients often have a distinct phenotype compared to other NF1 patients, including a more severe tumour burden. Our results suggest that reduced expression of HCA66, owing to haploinsufficiency of HCA66 gene, could render NF1 microdeleted patients-derived cells less susceptible to apoptosis.
Subject(s)
Antigens, Neoplasm/physiology , Apoptosis/physiology , Carrier Proteins/metabolism , Neurofibromatosis 1/physiopathology , Neurofibromin 1/genetics , Amino Acid Sequence , Animals , Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Apoptotic Protease-Activating Factor 1/genetics , Apoptotic Protease-Activating Factor 1/metabolism , Carrier Proteins/genetics , Caspase 3/genetics , Caspase 3/metabolism , Caspase 9/genetics , Caspase 9/metabolism , Cell Line , Cells, Cultured , Chromatography, Gel , Gene Deletion , HeLa Cells , Humans , Immunoblotting , Immunoprecipitation , Mice , Molecular Sequence Data , Neurofibromatosis 1/genetics , Neurofibromatosis 1/pathology , RNA, Small Interfering/genetics , RNA-Binding Proteins , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Syndrome , TransfectionABSTRACT
OBJECTIVES: A clinico-pathological study in diffuse systemic sclerosis (SSc) patients was performed to analyse whether the skin histological organization and the pro-fibrotic signals elicited by TGF-beta in fibroblasts vary according to the modified Rodnan skin score (mRSS). METHODS: Twenty-seven SSc patients underwent 45 skin biopsies with simultaneous measure of mRSS before or after treatment by immunosuppressive drugs, with or without autologous peripheral haematopoietic stem cell transplantation (HSCT). RESULTS: Double-blind optic microscopy analysis of the biopsies standard extracellular matrix stains allowed to define three histological subgroups: 6 with grade 1 weak fibrosis, 30 with grade 2 moderate fibrosis and 9 with grade 3 severe fibrosis. A significant (P < 0.0001) was identified between the grades of fibrosis and the mRSS. In skin fibroblast cultures, Smad3 phosphorylation levels, as well as mRNA steady-state levels of two transforming growth factor (TGF)-beta/Smad3 targets, COL1A2 and PAI-1, increased in parallel with the mRSS. When compared with pre-transplant values the degree of fibrosis observed after HSCT in the papillary and in the reticular dermis decreased in parallel with the fall in mRSS (n = 5 consecutive patients with repeated biopsies). CONCLUSIONS: The histological extent of skin fibrosis correlates closely with the mRSS. Both parameters appeared to regress after HSCT. The extent of TGF-beta signalling activation in SSc skin fibroblasts appears to parallel the severity of disease.
Subject(s)
Scleroderma, Diffuse/pathology , Severity of Illness Index , Skin/pathology , Adult , Aged , Biopsy , Cells, Cultured , Collagen/biosynthesis , Collagen/genetics , Collagen Type I , Combined Modality Therapy , Double-Blind Method , Female , Fibroblasts/metabolism , Fibrosis/metabolism , Fibrosis/pathology , Humans , Immunoenzyme Techniques , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Peripheral Blood Stem Cell Transplantation , Phosphorylation , Plasminogen Activator Inhibitor 1/biosynthesis , Plasminogen Activator Inhibitor 1/genetics , RNA, Messenger/genetics , Scleroderma, Diffuse/metabolism , Scleroderma, Diffuse/therapy , Signal Transduction , Skin/metabolism , Smad Proteins/metabolism , Smad3 Protein/metabolism , Transforming Growth Factor beta/metabolismABSTRACT
Stabilization of cytoplasmic beta-catenin is a hallmark of a variety of cancers. The stabilized beta-catenin is able to translocate to the nucleus, where it acts as a transcriptional activator of T-cell factor (TCF)-regulated genes. beta-Catenin may cross-talk with many signalling cascades to activate target genes. Whether beta-catenin cooperates with AP-1, another transcriptional complex activated during tumorigenesis is not fully clarified. We show that beta-catenin co-immunoprecipitates with c-Jun and c-Fos. GST pull-down experiments indicate a physical association of the armadillo repeat domain of beta-catenin with the DNA-binding domain of c-Jun and of the C-terminal domain of beta-catenin with the N-terminal domain of c-Fos. Promoter studies indicate that overexpression of AP-1 activates the transcription of two beta-catenin target genes, cyclin D1 and c-myc, by a mechanism independent of the AP-1 site, and fully dependent on the TCF-binding site. We further demonstrate that AP-1/beta-catenin synergism is involved during serum-induced cyclin D1 transcriptional activation. We identify a TCF-binding site on the cyclin D1 promoter which binds in vivo a complex induced by serum, containing beta-catenin, TCF4, c-Fos, c-Jun, JunB and JunD. This novel mechanism of interaction between two signalling cascades might contribute to the potentiation of malignancy.
Subject(s)
Gene Expression Regulation , TCF Transcription Factors/metabolism , Transcription Factor AP-1/metabolism , beta Catenin/metabolism , Animals , Binding Sites , Cell Proliferation , Cells, Cultured , Culture Media/pharmacology , Cyclin D1/genetics , Cyclin D1/metabolism , Gene Expression Regulation/drug effects , Humans , Promoter Regions, Genetic , Proto-Oncogene Proteins c-fos/genetics , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/genetics , Proto-Oncogene Proteins c-jun/metabolism , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , Signal Transduction , TCF Transcription Factors/genetics , Transcription Factor AP-1/genetics , Transcriptional Activation , beta Catenin/geneticsABSTRACT
c-fos, which encodes a transcription factor of the AP-1 family, is a prototypical immediate-early gene induced by a number of proinflammatory cytokines including interleukin-1 (IL-1), the latter being an important regulator of skin homeostasis. Using the human keratinocyte cell line HaCaT as an in vitro model, we dissected the molecular pathways leading to IL-1-induced c-fos gene induction. Phosphorylation of the transcription factor cAMP response element binding protein (CREB) at Ser133 was found to be essential for IL-1-induced c-fos gene induction and was closely paralleled by protein kinase A (PKA) activation. In contrast to other cell types, the cyclooxygenase/prostaglandin pathway, known to activate the cAMP/PKA cascade, plays little, if any, role in c-fos expression downstream of the IL-1 receptor in keratinocytes. Simultaneous activation of several of the mitogen-activated protein kinase (MAPK) cascades occurred in response to IL-1, but each differentially contributed to c-fos induction by IL-1, with the p38/MAPK being the most crucial of all, the extracellular signal-regulated kinase pathway contributing in an additive manner and the Jun N-terminal kinase pathway playing little, if any, role. We also demonstrate that p38-dependent activation of mitogen- and stress-activated kinase 1 (MSK1), a CREB kinase, is a key step for c-fos gene activation by IL-1. Finally, we identify MSK1 as playing a positive role in the control of cell proliferation of both HaCaT keratinocytes and the A431 human epidermoid carcinoma line.
Subject(s)
Cyclic AMP Response Element-Binding Protein/physiology , Interleukin-1/physiology , Keratinocytes/enzymology , Proto-Oncogene Proteins c-fos/biosynthesis , Proto-Oncogene Proteins c-fos/genetics , Ribosomal Protein S6 Kinases, 90-kDa/physiology , Animals , COS Cells , Cell Line , Cell Line, Tumor , Cell Proliferation , Chlorocebus aethiops , Humans , Keratinocytes/metabolism , Signal Transduction/physiologyABSTRACT
INTRODUCTION: Transforming Growth Factor beta 1 (TGFbeta1) is a key cytokine in the development of fibrotic diseases which are characterized by a pathological excess of extracellular matrix involving multiple organs. EXEGESIS: To induce its biological effects, TGFbeta1 interacts with Ser/Thr kinase receptor complexes. The polypeptide binding to the receptors induces TGFbeta intracellular mediator phosphorylation and namely Smad proteins. Upon phosphorylation the latter form protein complexes which are then translocated to the nucleus where they participate to matrix gene regulation. CONCLUSION: We will summarize the literature on the involvement of TGFbeta1 through the Smad proteins in fibrotic diseases.
Subject(s)
Fibrosis/physiopathology , Smad Proteins/physiology , Transforming Growth Factor beta/physiology , Humans , Kinetics , Transforming Growth Factor beta1ABSTRACT
Transforming growth factor-beta (TGF-beta) family members are multifunctional peptide growth factors that regulate cell growth, differentiation, extracellular matrix production and cell migration and embryonic development. Knock-out experiments for the three mammalian isoforms of TGF-beta in mice have demonstrated their importance in regulating inflammation and tissue repair. Also, TGF-beta has been implicated in the pathogenesis of human diseases, including tissue fibrosis and carcinogenesis. In the latter case, it may exert both tumor suppressor and pro-oncogenic activities depending on the stage of the tumor. Smads proteins constitute the core components of the intracellular signaling cascade initiated by TGF-beta receptors, as they carry signals from the cell surface directly to the nucleus; where they act as transcription factors.
Subject(s)
Transforming Growth Factor beta/physiology , Animals , DNA-Binding Proteins/physiology , Humans , Inflammation/physiopathology , Mice , Mice, Transgenic , Signal Transduction , Smad Proteins , Trans-Activators/physiology , Transforming Growth Factor beta/genetics , Wound HealingABSTRACT
Nephroblastoma overexpressed gene (NOV) is highly expressed in the nervous system. We investigated its biological activity by expressing the human NOV gene (NOVH) in a human glioblastoma cell line that is negative for NOVH and by analyzing four clones with different levels of NOVH expression. There was no difference in cell proliferation between the NOVH-expressing cell lines, but there was increased cell adhesion and migration that correlated with increasing NOVH expression. Gene expression profiling was used to investigate the mechanisms by which NOVH expression regulated cell activity. We identified two induced genes in NOVH-expressing cells that are involved in cell migration: matrix metalloprotease (MMP)3 and platelet-derived growth factor receptor (PDGFR)-alpha. Our studies show that PDGFR-alpha induced MMP3 gene expression and increased cell proliferation and cell migration upon stimulation by platelet-derived growth factor (PDGF)-AA. We also show that the induction of MMP3 in cells expressing NOVH is potentiated by either cell density, serum, or PDGF-BB. Thus, expression of NOVH in glioblastoma cells triggers a cascade of gene expression resulting in increased cell adhesion and migration.
Subject(s)
Brain Neoplasms/physiopathology , Cell Movement , Glioblastoma/physiopathology , Immediate-Early Proteins/pharmacology , Intercellular Signaling Peptides and Proteins/pharmacology , Matrix Metalloproteinase 3/biosynthesis , Becaplermin , Brain Neoplasms/enzymology , Brain Neoplasms/metabolism , Cell Adhesion/drug effects , Cell Movement/drug effects , Connective Tissue Growth Factor , Gene Expression Regulation , Glioblastoma/enzymology , Glioblastoma/metabolism , Humans , Matrix Metalloproteinase 3/genetics , Models, Biological , Nephroblastoma Overexpressed Protein , Platelet-Derived Growth Factor/pharmacology , Proto-Oncogene Proteins c-sis , Receptor, Platelet-Derived Growth Factor alpha/genetics , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Tumor Cells, CulturedABSTRACT
Metalloproteinases (MMPs) are essential regulators during various phases of the angiogenic process. These include the degradation of the basement membrane and the extracellular matrix, the mobilisation and activation of growth factors and the production of fragments with pro- or anti-angiogenic activity. In addition to their role in migration and invasion, MMPs can influence endothelial cell proliferation and survival by modifying the balance between angiogenic and anti-angiogenic molecules.
Subject(s)
Metalloendopeptidases/metabolism , Neovascularization, Physiologic , Animals , Basement Membrane , Cell Division , Cell Survival , Endothelium, Vascular/cytology , Extracellular Matrix , HumansABSTRACT
Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes either directly or in combination with other sequence-specific transcription factors. AP-1 sites and their cognate transcription factors also play important roles in the gene regulatory activities of TGF-beta. In this report, we have investigated the functional interactions of the Smad and AP-1 transcription factors. We demonstrate that Smad and AP-1 complexes specifically bind to their cognate cis-elements and do not interact with each other on-DNA, whereas off-DNA interactions occur between Smad3 and both c-Jun and JunB. Using both artificial constructs specific for either the Smad or AP-1 signaling pathways or natural promoters known to be TGF-beta-responsive, we have determined that Jun family members downregulate Smad3-mediated gene transactivation whereas AP-1-dependent promoters are synergistically activated by Smad3 and Jun proteins. We propose a model where the presence of Smad- and/or AP-1-specific cis-elements within TGF-beta-responsive genes allows dynamic modulation of gene expression, in contrast to the existing model where interactions between Smad and AP-1 proteins are merely an on/off mechanism to regulate TGF-beta/Smad targets.
Subject(s)
Activin Receptors, Type I , DNA-Binding Proteins/metabolism , Promoter Regions, Genetic/drug effects , Protein Serine-Threonine Kinases/drug effects , Receptors, Transforming Growth Factor beta/drug effects , Trans-Activators/metabolism , Transcription Factor AP-1/metabolism , Transcription, Genetic/drug effects , Transforming Growth Factor beta/pharmacology , Animals , Base Sequence , COS Cells , Cells, Cultured , Chlorocebus aethiops , Consensus Sequence , DNA/metabolism , Fibroblasts/cytology , Humans , Macromolecular Substances , Molecular Sequence Data , Oligodeoxyribonucleotides/metabolism , Oligopeptides , Peptides/immunology , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins c-jun/metabolism , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/physiology , Regulatory Sequences, Nucleic Acid , Signal Transduction/drug effects , Smad3 Protein , Substrate Specificity , Transcriptional Activation , TransfectionABSTRACT
Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes. Among the latter are c-jun and junB, which encode members of the AP-1 family of transcription factors. In this study, we have investigated the functional interactions of the Smad and AP-1 transcription factors in the context of Smad-specific gene transactivation in both fibroblasts and keratinocytes. We demonstrate that overexpression of either junB or c-jun prevents TGF-beta- or Smad3-induced transactivation of the Smad-specific promoter construct (SBE)(4)-Lux. Inversely, Smad-driven promoter transactivation by TGF-beta/Smad is significantly enhanced when c-jun expression is abolished in HaCaT keratinocytes, and when junB expression is prevented in fibroblasts, consistent with the cell-type specific induction of jun members by TGF-beta. We also demonstrate that Smad-specific gene transactivation in junB(-/-) mouse embryonic fibroblasts is significantly higher than in embryonic fibroblasts from the control parental mouse line, and that this difference is abolished by rescuing junB expression in junB(-/-) cells. Finally, we have determined that off-DNA interactions between Smad3 and both c-Jun and JunB result in the reduction of Smad3/DNA interactions. From these results, we provide a model in which jun expression in response to the initial Smad cascade represents a negative feed-back mechanism counteracting Smad-driven gene transactivation.
Subject(s)
DNA-Binding Proteins/physiology , Proto-Oncogene Proteins c-jun/biosynthesis , Trans-Activators/physiology , Transcription Factor AP-1/biosynthesis , Transcriptional Activation/physiology , Transforming Growth Factor beta/physiology , Animals , COS Cells , DNA/genetics , DNA/metabolism , DNA, Antisense/genetics , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/genetics , Fibroblasts/physiology , Genes, jun/genetics , Humans , Keratinocytes/physiology , Mice , Proto-Oncogene Proteins c-jun/genetics , Smad3 Protein , Trans-Activators/antagonists & inhibitors , Trans-Activators/genetics , Transcription Factor AP-1/genetics , Transcription Factor AP-1/physiology , Transfection , Transforming Growth Factor beta/antagonists & inhibitorsABSTRACT
Fibrosis is a consequence of injury characterized by accumulation of excess collagen and other extracellular matrix components, resulting in the destruction of normal tissue architecture and loss of function. Sp1 was originally described as a ubiquitous transcription factor. It is involved in the basal expression of extracellular matrix genes and may, therefore, be important in fibrotic processes. To evaluate the effect of Sp1 blockade on the expression of extracellular matrix genes, clones of NIH 3T3 fibroblasts stably transfected with an anti-sense Sp1 expression vector. Simultaneously reduced expression of several extracellular matrix genes as compared with mock-transfected clones was noted using differential hybridization of cDNA microarrays, without significant alteration in cell growth. Transfection of human dermal fibroblasts with several extracellular matrix gene (COL1A1, COL1A2, COL3A1, COL5A2, COL7A1, TIMP-1, and decorin) promoter/reporter constructs demonstrated that anti-sense Sp1-induced reduction of extracellular matrix gene mRNA steady-state levels results from transcriptional repression, consistent with the role of Sp1 as a transcription factor. Decoy Sp1 binding oligonucleotides inhibited COL1A2 promoter activity both in cultured fibroblasts and in vivo, in the skin of transgenic mice, which have integrated a mouse COL1A2 promoter/luciferase reporter gene construct. These results indicate that targeting Sp1 efficiently blocks extracellular matrix gene expression, and suggest that such an approach may represent an interesting therapeutic alternative toward the treatment of fibrotic disorders.
Subject(s)
Extracellular Matrix/genetics , Fibroblasts/pathology , Gene Expression/physiology , Sp1 Transcription Factor/antagonists & inhibitors , 3T3 Cells , Animals , Antisense Elements (Genetics)/pharmacology , Binding Sites , Cells, Cultured , Collagen/genetics , Collagen Type I , DNA, Complementary/genetics , Extracellular Matrix/drug effects , Extracellular Matrix/physiology , Fibroblasts/physiology , Fibrosis , Gene Expression/drug effects , Genes, Reporter/drug effects , Genes, Reporter/physiology , Humans , Mice , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic/drug effects , Promoter Regions, Genetic/physiology , Sp1 Transcription Factor/genetics , Sp1 Transcription Factor/metabolism , TransfectionABSTRACT
Despite major advances in the understanding of the intimate mechanisms of transforming growth factor-beta (TGF-beta) signaling through the Smad pathway, little progress has been made in the identification of direct target genes. In this report, using cDNA microarrays, we have focussed our attention on the characterization of extracellular matrix-related genes rapidly induced by TGF-beta in human dermal fibroblasts and attempted to identify the ones whose up-regulation by TGF-beta is Smad-mediated. For a gene to qualify as a direct Smad target, we postulated that it had to meet the following criteria: (1) rapid (30 min) and significant (at least 2-fold) elevation of steady-state mRNA levels upon TGF-beta stimulation, (2) activation of the promoter by both exogenous TGF-beta and co-transfected Smad3 expression vector, (3) up-regulation of promoter activity by TGF-beta blocked by both dominant-negative Smad3 and inhibitory Smad7 expression vectors, and (4) promoter transactivation by TGF-beta not possible in Smad3(-/-) mouse embryo fibroblasts. Using this stringent approach, we have identified COL1A2, COL3A1, COL6A1, COL6A3, and tissue inhibitor of metalloproteases-1 as definite TGF-beta/Smad3 targets. Extrapolation of this approach to other extracellular matrix-related gene promoters also identified COL1A1 and COL5A2, but not COL6A2, as novel Smad targets. Together, these results represent a significant step toward the identification of novel, early-induced Smad-dependent TGF-beta target genes in fibroblasts.
Subject(s)
Collagen/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Fibroblasts/metabolism , Gene Expression Regulation/physiology , Multigene Family , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic , Skin/metabolism , Trans-Activators/genetics , Trans-Activators/metabolism , Transcription, Genetic , Transcriptional Activation , Transforming Growth Factor beta/pharmacology , Animals , DNA-Binding Proteins/deficiency , Fibroblasts/cytology , Gene Expression Regulation/drug effects , Humans , Mice , Mice, Knockout , Molecular Sequence Data , RNA, Messenger/genetics , Skin/cytology , Smad3 Protein , Smad7 Protein , Tissue Inhibitor of Metalloproteinase-1/genetics , Trans-Activators/deficiency , Transcription, Genetic/drug effectsABSTRACT
Type VII collagen is the major collagenous component of the anchoring fibrils, attachment structures that stabilize the association of the cutaneous basement membrane zone to the underlying dermis. It is expressed by both epidermal keratinocytes and dermal fibroblasts. In this study, we have examined the pharmacological control of COL7A1 gene expression by the glucocorticorticoid dexamethasone. We demonstrate that dexamethasone is a potent transcriptional inhibitor of COL7A1 promoter activity in dermal fibroblasts, and we identify a potential glucocorticoid response element in the region -318/-212 of the promoter. In addition, we have determined that dexamethasone antagonizes transforming growth factor-beta (TGF-beta) activation of the COL7A1 promoter. This effect occurred without dexamethasone interfering with TGF-beta-induced Smad-specific gene transcription. These results indicate potential deleterious effects of glucocorticosteroids on epidermal wound healing, as reduced COL7A1 expression likely leads to decreased anchoring fibril formation, which may translate into delayed or impaired reepithelialization.
Subject(s)
Collagen/genetics , Dexamethasone/pharmacology , Down-Regulation/drug effects , Gene Expression Regulation/drug effects , Glucocorticoids/pharmacology , Skin/drug effects , Cells, Cultured , Collagen/biosynthesis , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Skin/metabolism , Transfection , Transforming Growth Factor beta/antagonists & inhibitors , Transforming Growth Factor beta/metabolismABSTRACT
The TNF-alpha receptor-associated factor 2 (TRAF2) and its downstream mediator, the NF-kappa B-inducing kinase (NIK), have been shown to induce NF-kappa B activation in 293 cells. Investigating the role these mediators play in human skin, we found that both NIK and TRAF2 failed to evoke transcription from NF-kappa B-dependent promoters linked to the CAT reporter in human dermal fibroblast cultures, while epidermal keratinocyte cultures demonstrated NIK-dependent signaling. Further, NF-kappa B activation by TNF-alpha was unaffected by overexpression of a dominant negative mutant NIK in fibroblasts, despite detection of endogenous TRAF2 and NIK by Western analysis. To explore alternative signaling mechanisms in dermal fibroblasts, we found that the intracellular calcium chelator, 3,4,5-trimethoxybenzoic acid, and the calpain inhibitor, N-acetyl-Leu-Leu-norleucinal, both blocked NF-kappa B activation; however, the specific proteosome inhibitor, lactacystin, failed to do so. Furthermore, TNF-alpha receptor mutants lacking a functional death domain failed to stimulate NF-kappa B, while phosphatidylcholine-phospholipase C inhibition and alkalization of endolysosomal compartments blocked its activation by TNF-alpha. These data indicate that, while epidermal keratinocytes utilize previously defined, NIK-dependent NF-kappa B pathways, dermal fibroblasts demonstrate unique NIK/TRAF2-independent signal transduction, where both acidic sphingomyelinase and calpain activity act as surrogate mediators for NF-kappa B activation.
Subject(s)
Arabidopsis Proteins , NF-kappa B/physiology , Tumor Necrosis Factor-alpha/pharmacology , Calcium/physiology , Cells, Cultured , Ceramides/physiology , Fatty Acid Desaturases/physiology , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Protein Serine-Threonine Kinases/physiology , Proteins/physiology , Skin/cytology , TNF Receptor-Associated Factor 1 , TNF Receptor-Associated Factor 2 , NF-kappaB-Inducing KinaseABSTRACT
Understanding the molecular mechanisms underlying the antagonistic activities of tumor necrosis factor-alpha (TNF-alpha) against transforming growth factor-beta (TGF-beta) is of utmost importance given the physiopathological implications of these cytokines. In this report, we demonstrate that TNF-alpha prevents TGF-beta-induced Smad-specific gene transactivation without inducing detectable levels of inhibitory Smad7 in human dermal fibroblasts. On the other hand, c-Jun and JunB, both induced by TNF-alpha, block Smad3-mediated transcription. Expression of antisense c-Jun mRNA prevents TNF-alpha inhibition of TGF-beta/Smad signaling whereas that of dominant-negative Ikappa-B kinase-alpha or antisense Smad7 does not. We provide evidence for off-DNA interactions between Smad3 and both c-Jun and JunB accompanied with reduced Smad3-DNA interactions. Finally, we show that overexpression of the transcriptional co-activator p300 prevents TNF-alpha/AP-1 inhibition of TGF-beta/Smad signaling. These data suggest that TNF-alpha interferes with Smad signaling through the induction of AP-1 components, the latter forming off-DNA complexes with Smad3 and preventing its binding to specific cis-element(s). In addition, Jun members compete with Smad3 for the common transcription co-activator p300. These two mechanisms are likely to act in concert to decrease Smad-specific transcription.
Subject(s)
Trans-Activators/metabolism , Transcription Factor AP-1/metabolism , Transcriptional Activation , Transforming Growth Factor beta/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Cells, Cultured , DNA-Binding Proteins/metabolism , Dermis/cytology , Dermis/metabolism , Drug Antagonism , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , I-kappa B Kinase , Nuclear Proteins/metabolism , Protein Binding , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins c-jun/metabolism , RNA, Antisense/pharmacology , Signal Transduction , Smad3 Protein , Smad7 ProteinABSTRACT
The expression of type XV collagen was studied in cultured human dermal fibroblasts exposed to transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha) or interleukin-1beta (IL-1beta), cytokines which have been shown previously to alter the expression of several extracellular matrix genes. TGF-beta enhanced the expression of the type XV collagen gene (COL15A1) in a time-dependent manner, up to 4.3-fold after 24 h of incubation, whereas TNF-alpha and IL-1beta reduced the mRNA steady-state levels by 32 and 80%, respectively. When TGF-beta and TNF-alpha were added together to the cultures, the stimulatory effect of TGF-beta on type XV collagen gene expression was abrogated, indicating antagonistic modulation by these 2 cytokines. These data suggest that the cytokines tested in this study may contribute to the regulation of type XV collagen synthesis in a variety of tissues which have recently been shown to express this particular collagen gene.
Subject(s)
Collagen/genetics , Cytokines/pharmacology , Fibroblasts/drug effects , Fibroblasts/metabolism , Skin/drug effects , Skin/metabolism , Cells, Cultured , Gene Expression/drug effects , Humans , Interleukin-1/pharmacology , Kinetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Skin/cytology , Transforming Growth Factor beta/administration & dosage , Transforming Growth Factor beta/pharmacology , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Among its plethora of activities as an inflammatory mediator, TNF-alpha has potent regulatory control on extracellular matrix production and degradation. Earlier studies have documented that TNF-alpha inhibits type I collagen gene (COL1A2) expression at the transcriptional level, but the characterization of the transcription factors involved has been elusive. In the present study, using transient cell transfection of human dermal fibroblasts with a battery of 5' end deletion/chloramphenicol acetyltransferase (CAT) reporter gene constructs, we have characterized the TNF-alpha response element of the COL1A2 promoter. The TNF-alpha response element was attributed to a specific region that comprises noncanonical activator protein-1 (AP-1) (CGAGTCA) and NF-kappa B (AGAGTTTCCC) binding sites. TNF-alpha effect was eliminated by a 2-bp substitution mutation in the NF-kappa B1 binding half site of the NF-kappa B cis element. Electrophoretic mobility shift assays (EMSA) showed that recombinant human NF-kappa B heterodimers as well as NF-kappa B1 and RelA homodimers, but not AP-1, were capable of binding this element. Further, EMSA with human fibroblast nuclear extracts demonstrated enhanced binding of a single, specific complex within 5 min of TNF-alpha stimulation, which reached a plateau by 1 h and was not affected by preincubation of cells with cycloheximide. Gel supershift assays identified the complex as the NF-kappa B (p50/p65) heterodimer, whereas Abs to nuclear factor of activated T cells (NF-AT) and Jun family members failed to recognize the complex. These data suggest that in fibroblasts TNF-alpha activates and initiates the nuclear translocation of NF-kappa B that binds a divergent NF-kappa B element and plays a critical role in the observed inhibition of alpha 2(I) collagen gene transcription.
Subject(s)
Collagen/antagonists & inhibitors , Collagen/genetics , Fibroblasts/metabolism , Gene Expression Regulation/immunology , NF-kappa B/metabolism , Tumor Necrosis Factor-alpha/physiology , Carrier Proteins/isolation & purification , Cells, Cultured , Humans , Mutation/immunology , Promoter Regions, Genetic/immunology , Protein Binding/immunology , Response Elements/immunology , Tumor Necrosis Factor-alpha/geneticsABSTRACT
We have previously demonstrated that transforming growth factor-beta (TGF-beta) and pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interleukin-1beta, synergistically enhance the expression of type VII collagen gene (COL7A1) in human dermal fibroblasts in culture (Mauviel et al., 1994). Recently, we identified a SMAD-containing complex, rapidly induced by TGF-beta and binding the region [-496/-444] of the COL7A1 promoter, responsible for COL7A1 gene transactivation (Vindevoghel et al., 1998a). In this report, we demonstrate that TGF-beta and TNF-alpha response elements are distinct entities within the COL7A1 promoter. In particular, we demonstrate that the TNF-alpha effect is mediated by NF-kappaB1/RelA (p50/p65) and RelA/RelA (p65/p65) NF-kappaB complexes binding the TNF-alpha response element (TaRE) located in the region [-252/-230], with RelA acting as the transcriptional activator. Finally, we provide definitive evidence for the role of both TGF-beta and TNF-alpha response elements as enhancer sequences, functioning in the context of a heterologous promoter in an additive manner in response to TGF-beta and TNF-alpha. This study provides the first identification of a functional interaction between the two immediate-early transcription factors, SMAD and NF-kappaB, to activate the expression of an extracellular matrix-related gene, COL7A1.